Fungal infection in cardiothoracic transplant recipients: outcome without systemic amphotericin therapy

Area of Science:

• Medical Mycology
• Transplantation Immunology
• Infectious Diseases

Background:

• Transplant recipients require immunosuppression, increasing susceptibility to opportunistic fungal infections.
• Managing these infections is challenging due to diagnostic difficulties, treatment resistance, drug interactions, and toxicity.
• Current treatment guidelines often rely on Amphotericin B, which has significant side effects.

Purpose of the Study:

• To evaluate the efficacy and safety of systemic non-Amphotericin-based antifungal therapies in transplant recipients.
• To assess treatment outcomes using established criteria for fungal infections and treatment response.
• To explore the potential benefits of early treatment initiation based on clinical criteria.

Main Methods:

• Retrospective analysis of inpatient antifungal therapy from September 2005 to December 2010.
• Inclusion of 249 transplant recipients (204 lung, 45 heart) treated with systemic antifungals.
• Classification of fungal infections using European Organization for Research and Treatment of Cancer (EORTC) criteria and outcomes similar to clinical trials.

Main Results:

• A high overall response rate was observed with non-Amphotericin-based antifungals.
• 165 patients achieved a complete response, 24 a partial response, and 60 had unsuccessful treatment.
• Voriconazole and Caspofungin were frequently used, often in combination.

Conclusions:

• Systemic non-Amphotericin-based antifungal therapy demonstrates high efficacy in transplant recipients.
• Early treatment initiation, guided by clinical criteria rather than solely positive fungal identification, is feasible and effective.
• This approach offers a promising strategy with a favorable side effect profile for managing fungal infections in this vulnerable population.